Suppliers / Corden Pharma Chenove

Corden Pharma Chenove

France Updated 9 July 2026

Corden Pharma Chenove is an API manufacturer based in France. It holds 7 active US drug master files across a filed portfolio of 6 molecules. Its GMP standing is certified by ANSM (FR), EMA and US FDA. Its most recent recorded inspection, by US FDA, closed on 14 February 2025 as VAI.

7
active US DMFs
0
valid CEPs
2
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
5 of 5 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 14 February 2025 VAI US FDA
  • 13 September 2019 VAI US FDA
  • 26 August 2016 NAI US FDA
  • 14 March 2014 VAI US FDA
  • 20 November 2009 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
France, France 3002808295
Chenove, France Not on file

What they file, and where

Molecule Regulators Docs
Fenofibrate SFDA (Saudi Arabia), US FDA 3
Bisoprolol US FDA 1
Choline Salicylate US FDA 1
Nebivolol US FDA 1
Oxybutynin US FDA 1
Tetrabenazine US FDA 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
ANSM (FR) None 17
EMA None 2
US FDA None 1

Comparing suppliers?

Choose your molecules and target markets. Corden Pharma Chenove comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 14 February 2025.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates